121 related articles for article (PubMed ID: 34811896)
61. Randomized phase II study of second-line chemotherapy with the best available 5-fluorouracil regimen versus weekly administration of paclitaxel in far advanced gastric cancer with severe peritoneal metastases refractory to 5-fluorouracil-containing regimens (JCOG0407).
Nishina T; Boku N; Gotoh M; Shimada Y; Hamamoto Y; Yasui H; Yamaguchi K; Kawai H; Nakayama N; Amagai K; Mizusawa J; Nakamura K; Shirao K; Ohtsu A;
Gastric Cancer; 2016 Jul; 19(3):902-10. PubMed ID: 26386560
[TBL] [Abstract][Full Text] [Related]
62. A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer.
Kollmannsberger C; Quietzsch D; Haag C; Lingenfelser T; Schroeder M; Hartmann JT; Baronius W; Hempel V; Clemens M; Kanz L; Bokemeyer C
Br J Cancer; 2000 Aug; 83(4):458-62. PubMed ID: 10945491
[TBL] [Abstract][Full Text] [Related]
63. Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
Northfelt DW; Allred JB; Liu H; Hobday TJ; Rodacker MW; Lyss AP; Fitch TR; Perez EA;
Am J Clin Oncol; 2014 Apr; 37(2):167-71. PubMed ID: 23211220
[TBL] [Abstract][Full Text] [Related]
64. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
[TBL] [Abstract][Full Text] [Related]
65. Intraperitoneal Paclitaxel Combined with S-1 Plus Oxaliplatin for Advanced Gastric Cancer with Peritoneal Metastasis: a Phase I Study.
Kim DW; Seo WJ; Youn SI; Jee YS; Jang YJ; Kim JH;
J Gastric Cancer; 2021 Dec; 21(4):418-425. PubMed ID: 35079443
[TBL] [Abstract][Full Text] [Related]
66. A Prospective Phase I/II Study of Docetaxel, Cisplatin and Continuous Capecitabine in Advanced Oesophago-Gastric Cancer (NWCOG-3).
Gollins S; Massalha S; Mullard A; Williams RM; Lloyd A; Morris J; Garcia-Alonso A
Clin Oncol (R Coll Radiol); 2018 Jul; 30(7):409-417. PubMed ID: 29573846
[TBL] [Abstract][Full Text] [Related]
67. Alternative intraperitoneal chemotherapy regimens for optimally debulked ovarian cancer.
Gray HJ; Shah CA; Swensen RE; Tamimi HK; Goff BA
Gynecol Oncol; 2010 Mar; 116(3):340-4. PubMed ID: 19922987
[TBL] [Abstract][Full Text] [Related]
68. [The updated treatment strategy for gastric cancer with peritoneal metastasis].
Ishigami H; Kaisaki S; Kitayama J
Nihon Geka Gakkai Zasshi; 2012 Jan; 113(1):18-21. PubMed ID: 22413551
[TBL] [Abstract][Full Text] [Related]
69. Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases.
Saito S; Yamaguchi H; Ohzawa H; Miyato H; Kanamaru R; Kurashina K; Hosoya Y; Lefor AK; Sata N; Kitayama J
Ann Surg Oncol; 2021 Jul; 28(7):3863-3870. PubMed ID: 33270170
[TBL] [Abstract][Full Text] [Related]
70. Intraperitoneal Administration of Paclitaxel Followed by Paclitaxel, Cisplatin, and S-1 Chemotherapy for Cytology-positive Gastric Cancer: A Feasibility Study.
Shinkai M; Imano M; Chiba Y; Hiraki Y; Kato H; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T
Anticancer Res; 2018 Oct; 38(10):5969-5974. PubMed ID: 30275227
[TBL] [Abstract][Full Text] [Related]
71. Combined intraperitoneal and intravenous chemotherapy for women with optimally debulked ovarian cancer: results from an intergroup phase II trial.
Rothenberg ML; Liu PY; Braly PS; Wilczynski SP; Hannigan EV; Wadler S; Stuart G; Jiang C; Markman M; Alberts DS
J Clin Oncol; 2003 Apr; 21(7):1313-9. PubMed ID: 12663720
[TBL] [Abstract][Full Text] [Related]
72. [Treatment for advanced gastric cancer with positive lavage cytology-systemic versus intraperitoneal chemotherapy].
Iwasaki Y; Ohashi M; Nunobe S; Iwanaga T; Iwagami S; Takahashi K; Yamaguchi T; Matsumoto H; Nakano D
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2009-11. PubMed ID: 19106506
[TBL] [Abstract][Full Text] [Related]
73. A phase II trial of capecitabine plus cisplatin (XP) for patients with advanced gastric cancer with early relapse after S-1 adjuvant therapy: XParTS-I trial.
Nishikawa K; Tsuburaya A; Yoshikawa T; Takahashi M; Tanabe K; Yamaguchi K; Yoshino S; Namikawa T; Aoyama T; Rino Y; Kawada J; Tsuji A; Taira K; Kimura Y; Kodera Y; Hirashima Y; Yabusaki H; Hirabayashi N; Fujitani K; Miyashita Y; Morita S; Sakamoto J
Gastric Cancer; 2018 Sep; 21(5):811-818. PubMed ID: 29488122
[TBL] [Abstract][Full Text] [Related]
74. Phase I study of combination chemotherapy consisting of paclitaxel, cisplatin, and S-1 in patients with unresectable gastric cancer (KOGC-02).
Takahashi T; Saikawa Y; Fukuda K; Funakoshi S; Kawakubo H; Takeuchi H; Takaishi H; Kitagawa Y
Anticancer Res; 2012 Dec; 32(12):5401-6. PubMed ID: 23225443
[TBL] [Abstract][Full Text] [Related]
75. Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Armstrong DK; Bundy B; Wenzel L; Huang HQ; Baergen R; Lele S; Copeland LJ; Walker JL; Burger RA;
N Engl J Med; 2006 Jan; 354(1):34-43. PubMed ID: 16394300
[TBL] [Abstract][Full Text] [Related]
76. Utilization of an Alternative Docetaxel-based Intraperitoneal Chemotherapy Regimen in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma: A Continued Need for Ovarian Cancer Patients.
Becker DA; Leath CA; Walters-Haygood CL; Smith BQ; Bevis KS
Am J Clin Oncol; 2019 Jan; 42(1):12-16. PubMed ID: 29782365
[TBL] [Abstract][Full Text] [Related]
77. Modified docetaxel, cisplatin, and 5-fluorouracil combination regimen and capecitabine maintenance in metastatic gastric cancer: toxicity and efficacy results.
Arslan C; Atilla FD
Support Care Cancer; 2022 May; 30(5):4447-4455. PubMed ID: 35106659
[TBL] [Abstract][Full Text] [Related]
78. Phase I and pharmacodynamic study of vorinostat combined with capecitabine and cisplatin as first-line chemotherapy in advanced gastric cancer.
Yoo C; Ryu MH; Na YS; Ryoo BY; Lee CW; Maeng J; Kim SY; Koo DH; Park I; Kang YK
Invest New Drugs; 2014 Apr; 32(2):271-8. PubMed ID: 23712440
[TBL] [Abstract][Full Text] [Related]
79. Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): a multicenter, phase II trial.
Gong J; Liu T; Fan Q; Bai L; Bi F; Qin S; Wang J; Xu N; Cheng Y; Bai Y; Liu W; Wang L; Shen L
BMC Cancer; 2016 Feb; 16():68. PubMed ID: 26857702
[TBL] [Abstract][Full Text] [Related]
80. Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination.
Fujiwara Y; Nishida T; Takiguchi S; Nakajima K; Miyata H; Yamasaki M; Yamamoto K; Moon JH; Mori M; Doki Y
Anticancer Res; 2010 Apr; 30(4):1335-9. PubMed ID: 20530449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
